# A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

> **NCT04226989** · EARLY_PHASE1 · UNKNOWN · sponsor: **He Huang** · enrollment: 72 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** CT-RD06

## Key facts

- **NCT ID:** NCT04226989
- **Lead sponsor:** He Huang
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-05
- **Primary completion:** 2022-02-05
- **Final completion:** 2024-05-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2020-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226989, "A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04226989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*